6.795

0.07% -0.005

Olema Pharmaceuticals Inc (OLMA)

Overview News Price History Option Chain Financials Discussions Forecast

Olema Pharmaceuticals Inc stock is traded at $6.795, with a volume of 585.28K. It is down -0.07% in the last 24 hours and down -30.52% over the past month. Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Previous Close:

$6.80

Open:

$6.84

24h Volume:

585.28K

Relative Volume:

0.49

Market Cap:

$594.55M

Revenue:

Net Income/Loss:

$-185.15M

P/E Ratio:

-3.3551

EPS:

-2.0253

Net Cash Flow:

$-148.72M

1W Performance:

-13.11%

1M Performance:

-30.52%

6M Performance:

-58.79%

1Y Performance:

-34.47%

1-Day Range:

$6.70

$6.91

1-Week Range:

$6.61

$8.00

52-Week Range:

$6.61

$36.26

Olema Pharmaceuticals Inc Stock (OLMA) Company Profile

Name

Olema Pharmaceuticals Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(415) 651-3316

Address

780 BRANNAN STREET, SAN FRANCISCO

Employee

131

Twitter

Next Earnings Date

2026-11-09

Latest SEC Filings

OLMA's Discussions on Twitter

Compare OLMA vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OLMA Olema Pharmaceuticals Inc	6.795	594.55M	0	-185.15M	-148.72M	-2.0253
VRTX Vertex Pharmaceuticals Inc	508.13	128.79B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	238.40	95.18B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	798.88	82.25B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.25	53.66B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.30	42.34B	5.76B	514.49M	1.10B	4.4813

Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	Wolfe Research	Peer Perform
Mar-19-26	Resumed	Jefferies	Buy
Feb-11-26	Initiated	Stifel	Buy
Jan-07-26	Initiated	Piper Sandler	Overweight
Oct-08-25	Initiated	Guggenheim	Buy
Aug-12-25	Reiterated	Citigroup	Buy
Apr-02-24	Initiated	Goldman	Buy
Jan-30-24	Initiated	Citigroup	Buy
Jul-21-23	Initiated	Oppenheimer	Outperform
May-05-23	Initiated	CapitalOne	Overweight
Feb-22-23	Initiated	Credit Suisse	Outperform
Jul-06-22	Resumed	Canaccord Genuity	Buy
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight
Dec-14-20	Initiated	Jefferies	Buy

View All

Olema Pharmaceuticals Inc Stock (OLMA) Latest News

Oct 02, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2026

Sep 29, 2026

Bank of America Corp DE Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat

Sep 29, 2026

Sep 19, 2026

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com

Sep 19, 2026

Sep 14, 2026

Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results - Yahoo Finance

Sep 14, 2026

Sep 11, 2026

Olema Pharmaceuticals (OLMA) Shares Drop 15% After AstraZeneca B - GuruFocus

Sep 11, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 4.4%Here's Why - MarketBeat

Sep 11, 2026

Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $59 - Moomoo

Sep 11, 2026